Moreover, the NF-κB inhibitor BMS-345541, targeting IKKα/β, has been shown to reduce extramedullary hematopoiesis, BM fibrosis, and osteosclerosis and to alleviate inflammation, as indicated by decreased levels of IL-1β and TNF [47]. Here, IL1B is linked to osteosclerosis.